- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01976013
Prediction of Major Bleeding in ELBW-infants (<1000g) by Sequential Coagulation Monitoring
Prediction of Major Bleeding in Extremely Low Birth Weight Infants (<1000g) by Sequential Coagulation Monitoring
Study Overview
Status
Intervention / Treatment
Detailed Description
It was recently reported that "early", i.e. in the first 48h of life, coagulation screening may identify infants at risk of severe IVH. Unfortunately, in the past screening for coagulation abnormalities and correction of haemostatic defects by prothrombin complex concentrate, cryoprecipitate or platelet concentrates) and fresh frozen plasma (FFP) had limited effects in preterm infants. This could have been due to the short duration of action, incomplete restoration of coagulation or the water and osmotic load associated with FFP administration. However recently, using a coagulopathy screening strategy (one blood sample within the first 2h after birth) and substitution with FFP decreased the risk of developing IVH in infants born at 23 to 26 weeks of gestation. Recombinant Factor VII (rFVII) provides a new therapeutic option to overcome FFP associated side effects. Small trials, including infants with pulmonary hemorrhage, showed the safety and effectiveness of rFVII in VLBW infants; however no randomised controlled trials have been published so far. As outlined above, bleeding complications are still a major problem in extremely low birth weight (ELBW) infants and coagulation abnormalities are associated with bleeding. Up to now, only data about early and single screening exist and coagulation monitoring with multiple blood sampling was not applied.
In neonatal practice, coagulation abnormality in preterm babies is primarily investigated by measuring prothrombin time (PT). In fact, FVII activity, which is an important determinant of PT, is strongly associated with bleeding risk. Thus, a method to measure PT with small volume samples (10μL) provides the possibility for serial monitoring even in ELBW infants.
Substitution of FFP seemed beneficial in ELBW infants and first trials with rFVII revealed promising results in this patient population. Thus, coagulation monitoring might lead to early and adequate therapy and therefore to better outcome.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University of Vienna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Preterm infants with a birth weight <1000g
- signed informed consent
Exclusion Criteria:
- Congenital heart disease
- major congenital birth defects
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Coaguchek
infants will receive sequential coagulation checks
|
The investigators plan to draw 10μL blood (i.e.
approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling.
Thus, the number of blood samples will be variable.
A cumulative sample volume for the whole study period will not exceed 300μL.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
major bleeding
Time Frame: 30 days
|
pulmonary bleeding, intraventricular hemorrhage
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
mortality
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MUV-Coagu
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intraventricular Haemorrhage
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownPostpartum Haemorrhage | Intraventricular Haemorrhage | Delayed Umbilical Cord Clamping BenefitsSpain
-
King Saud Medical CityUnknownIntraventricular Haemorrhage NeonatalSaudi Arabia
-
Sharp HealthCareEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedDeath; Neonatal | Intraventricular Haemorrhage NeonatalUnited States, Ireland, Canada, Germany
-
Mount Sinai Hospital, CanadaLondon Health Sciences Centre; Royal Alexandra Hospital; Foothills Medical CentreRecruitingIntraventricular Hemorrhage of Newborn Grade 2 | Intraventricular Hemorrhage of Newborn Grade 3 | Intraventricular Haemorrhage Grade IVCanada
-
University of Maryland, BaltimoreRecruitingIntra Cerebral Hemorrhage | Subarachnoid Hemorrhage | Intraventricular Hemorrhage | Nontraumatic HaemorrhageUnited States
-
University of Maryland, BaltimoreNico CorporationRecruitingIntracerebral Haemorrhage, IntraventricularUnited States
-
Assiut UniversityUnknownEndoscopy in Intraventricular Lesions
-
Nanjing PLA General HospitalUnknownIntraventricular Hemorrhage, Endoscopic Intraventricular Evacuation Surgery, Extraventricular DrainageChina
-
Sharp HealthCareEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Children's Hospital Medical Center, CincinnatiRecruitingIntraventricular HemorrhageUnited States
Clinical Trials on Coaguchek
-
Hoffmann-La RocheWithdrawnCardiovascular AbnormalitiesCanada
-
Medical University of ViennaUnknown
-
Hospital de BaseNot yet recruitingCoaguChek® XS System | Coagulation Function
-
Nationwide Children's HospitalCompletedCardiopulmonary Bypass | Spinal FusionUnited States
-
University College CorkHoffmann-La Roche; Health Research Board, Ireland; ZyCare IncUnknown
-
Montreal Heart InstituteRoche Diagnostic Ltd.CompletedQuality of Life | Anticoagulants | Drug Monitoring | Pharmacy | Ambulatory CareCanada
-
University Hospital, BordeauxHoffmann-La Roche; Ministry of Health, France; BiodisCompletedMechanical Prosthetic Heart Valve Implantation | Patient Self Monitoring of Oral Anticoagulent TherapyFrance
-
University of FloridaHoffmann-La RocheCompletedAntiphospholipid Antibody SyndromeUnited States
-
University of UlsterBelfast Health and Social Care TrustCompletedCongenital Heart Disease | Congenital Heart Defect | Adult Congenital Heart DiseaseUnited Kingdom